X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Clinical Trials News - 05/Sep 04:09

First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in an...

Articles similaires

Sorry! Image not available at this time

Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases

pharmabiz.com - 05/Sep 00:00

Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...

Sorry! Image not available at this time

Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases

pharmabiz.com - 05/Sep 00:00

Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...

Sorry! Image not available at this time

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML

drugs.com - 06/Sep 07:09

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...

Sorry! Image not available at this time

Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease

drugs.com - 14/Sep 05:09

LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological...

Sorry! Image not available at this time

Aura Biosciences announces positive results from phase 2 end of study of bel─sar as a first─line treatment for early─stage choroidal melanoma

pharmabiz.com - 14/Sep 23:19

Aura Biosciences, Inc., a clinical─stage biotechnology company developing precision therapies for solid tumours designed to preserve organ function,...

Sorry! Image not available at this time

Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia

pharmabiz.com - 13/Sep 16:48

Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...

Sorry! Image not available at this time

Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia

pharmabiz.com - 13/Sep 16:48

Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Les derniers communiqués